Alx Oncology Holdings Inc (ALXO)

05:15 AM

Alx oncology ceo Jason Lettmann sells shares for $2,483 By Investing.com - Investing.com South Africa

05:15 AM

05:15 AM

Alx oncology president Jaume Pons sells $1,525 in stock By Investing.com - Investing.com South Africa

05:15 AM

Feb 21, 2025

Alx oncology SVP Shelly Pinto sells $632 in common stock By Investing.com - Investing.com Nigeria

Feb 21, 2025

Feb 21, 2025

Alx oncology president Jaume Pons sells $1,525 in stock - Investing.com India

Feb 21, 2025

Feb 21, 2025

Alx oncology SVP Shelly Pinto sells $632 in common stock - Investing.com India

Feb 21, 2025

Feb 19, 2025

February 2025 US Penny Stocks With Promising Prospects - Yahoo Finance

Feb 19, 2025

Feb 18, 2025

Evorpacept shows promise in HER2-positive cancer trial - MSN

Feb 18, 2025

Feb 18, 2025

ALX Oncology to Host Virtual R&D Day on March 5, 2025 - GlobeNewswire

Feb 18, 2025

Feb 18, 2025

ALX Oncology Reveals Next-Gen Cancer Pipeline: Expert Panel to Unveil Evorpacept Breakthroughs - StockTitan

Feb 18, 2025

Feb 14, 2025

Analysts Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) Price Target at $3.05 - MarketBeat

Feb 14, 2025

Feb 11, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Feb 11, 2025

Feb 10, 2025

Recent Insider Activity Suggests Potential Gains for Alx Oncology Holdings Inc (ALXO) - Knox Daily

Feb 10, 2025

Feb 10, 2025

Market Momentum: Alx Oncology Holdings Inc (ALXO) Registers a -9.17 Decrease, Closing at 1.09 - The Dwinnex

Feb 10, 2025

Feb 06, 2025

An analyst sees good growth prospects for Alx Oncology Holdings Inc (ALXO) - SETE News

Feb 06, 2025

Feb 05, 2025

Is it possible to buy Alx Oncology Holdings Inc(ALXO) shares at a good price now? - US Post News

Feb 05, 2025

Feb 04, 2025

Alx Oncology Holdings Inc (ALXO) receives a Hold rating from Jefferies - Knox Daily

Feb 04, 2025

Feb 04, 2025

Form S-8Securities to be offered to employees in employee benefit plans - br.ADVFN.com

Feb 04, 2025

Feb 03, 2025

ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 9.4% in January - MarketBeat

Feb 03, 2025

Jan 28, 2025

ALX Oncology (NASDAQ:ALXO) Price Target Lowered to $2.20 at UBS Group - Defense World

Jan 28, 2025

Jan 27, 2025

H.C. Wainwright cuts ALX Oncology target to $5, keeps buy rating - MSN

Jan 27, 2025

Jan 27, 2025

UBS cuts ALX Oncology target to $2.20, keeps Buy rating By Investing.com - Investing.com UK

Jan 27, 2025

Jan 27, 2025

ALX Oncology (NASDAQ:ALXO) Price Target Cut to $2.20 by Analysts at UBS Group - MarketBeat

Jan 27, 2025

Jan 27, 2025

ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World

Jan 27, 2025

Jan 27, 2025

Analysts Issue Forecasts for ALX Oncology FY2029 Earnings - MarketBeat

Jan 27, 2025

Jan 27, 2025

HC Wainwright Comments on ALX Oncology FY2029 Earnings - Defense World

Jan 27, 2025

Jan 26, 2025

HC Wainwright Has Lowered Expectations for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World

Jan 26, 2025

Jan 25, 2025

ALX Oncology (NASDAQ:ALXO) Receives "Overweight" Rating from Cantor Fitzgerald - MarketBeat

Jan 25, 2025

Jan 25, 2025

ALX Oncology says evorpacept scores well in Phase II study - The Pharma Letter

Jan 25, 2025

Jan 24, 2025

Stifel maintains hold on ALX Oncology shares, keeps $3 target By Investing.com - Investing.com UK

Jan 24, 2025

Jan 24, 2025

ALX Oncology (NASDAQ:ALXO) Price Target Cut to $5.00 by Analysts at HC Wainwright - MarketBeat

Jan 24, 2025

Jan 24, 2025

Barclays PLC Grows Stock Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World

Jan 24, 2025

Jan 24, 2025

ALX Oncology Presents Positive Updated Data from ASPEN-06 - GlobeNewswire

Jan 24, 2025

Jan 24, 2025

Cantor Fitzgerald Forecasts ALX Oncology FY2025 Earnings - MarketBeat

Jan 24, 2025

Jan 24, 2025

Cantor Fitzgerald Predicts ALX Oncology FY2025 Earnings - Defense World

Jan 24, 2025

Jan 24, 2025

Evorpacept shows promise in HER2-positive cancer trial By Investing.com - Investing.com South Africa

Jan 24, 2025

Jan 23, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 23, 2025

Jan 23, 2025

ALX Oncology Shares Drop 15% Following Positive Phase 2 - GuruFocus.com

Jan 23, 2025

Jan 23, 2025

ALX Oncology stock falls 16% amid Phase 2 data update - MSN

Jan 23, 2025

Jan 23, 2025

Cantor Fitzgerald Weighs in on ALX Oncology FY2025 Earnings - MarketBeat

Jan 23, 2025

Jan 23, 2025

ALX Oncology Holdings Inc. Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer - Marketscreener.com

Jan 23, 2025

Jan 23, 2025

ALX Oncology (ALXO) Presents Positive Updated Data from ASPEN-06 Phase 2 Trial - StreetInsider.com

Jan 23, 2025

Jan 23, 2025

ALX Oncology's Evorpacept Shows Breakthrough 49% Response Rate in Gastric Cancer Trial - StockTitan

Jan 23, 2025

Jan 22, 2025

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules - The Manila Times

Jan 22, 2025

Jan 22, 2025

ALX Oncology Grants 600,000 Stock Options to New CFO Harish Shantharam at $1.65 - StockTitan

Jan 22, 2025

Jan 22, 2025

ALX Oncology Announces Further Additions to Leadership Team - GlobeNewswire

Jan 22, 2025

Jan 22, 2025

ALX Oncology Strengthens Leadership with Key Appointments - TipRanks

Jan 22, 2025

Jan 22, 2025

ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors - The Manila Times

Jan 22, 2025